Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 17/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946691 | 0.88 | HTR6 (0.75) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL948613 | 0.87 | HTR6 (0.63) | AKR1C3AKR1C1HTR6HTR1ADRD2 | |
| SCHEMBL947464 | 0.87 | HTR6 (0.56) | AKR1C3AKR1C1HTR6 | |
| SCHEMBL13125610 | 0.87 | HTR6 (0.79) | AKR1C3AKR1C1HTR6HTR1ADRD2 | |
| SCHEMBL13125603 | 0.86 | HTR6 (0.74) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL946516 | 0.86 | HTR6 (0.74) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL13125601 | 0.86 | HTR6 (0.63) | AKR1C3AKR1C1HTR6HTR1ADRD2 | |
| SCHEMBL950565 | 0.86 | HTR6 (0.74) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL946389 | 0.85 | HTR6 (0.56) | AKR1C3AKR1C1HTR6HTR1ADRD2 | |
| SCHEMBL950578 | 0.83 | HTR6 (0.54) | AKR1C3AKR1C1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101544592-B | Process for preparation of N-arylsulfonyl-3-substituted indoles | SUVEN LIFE SCIENCES LTD | 2013-08-21 | — | — | CN | disclosed |
| CN-1720225-B | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD | 2011-05-18 | — | — | CN | disclosed |
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7807705-B2 | Potent indole-3-carbinol-derived antitumor agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807705-B2 | Potent indole-3-carbinol-derived antitumor agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-05 | — | — | US | disclosed |
| CN-101544592-A | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LTD (IN) | 2009-09-30 | — | — | CN | disclosed |
| US-20080300291-A1 | POTENT INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300291-A1 | POTENT INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
| CN-1720225-A | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD (IN) | 2006-01-11 | — | — | CN | disclosed |
| EP-1581492-A1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004048330-A1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300291-A1 | POTENT INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS | CASP3, BAD, BAX | AKR1C3 535/4885AKR1C1 918/4885HTR6 113/4885 |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | AKR1C3 1274/4885AKR1C1 1906/4885HTR6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.